U.S. Pharmaceuticals & Biotech Mid-Large Cap Stocks

Bristol-Myers Squibb

Market Cap: US$113.1b

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

Johnson & Johnson

Market Cap: US$589.5b

Engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.

Zoetis

Market Cap: US$32.6b

Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.

Amgen

Market Cap: US$190.4b

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Gilead Sciences

Market Cap: US$153.8b

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

AbbVie

Market Cap: US$429.6b

A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.

Merck

Market Cap: US$309.8b

Operates as a healthcare company worldwide.

Phibro Animal Health

Market Cap: US$1.3b

Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.

Agilent Technologies

Market Cap: US$38.3b

Provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.

Pfizer

Market Cap: US$134.9b

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

Perrigo

Market Cap: US$1.3b

Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.

Danaher

Market Cap: US$136.7b

Designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.

Viatris

Market Cap: US$18.7b

Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.

Qiagen

Market Cap: US$8.1b

Provides sample to insight solutions that transform biological samples into molecular insights worldwide.

Royalty Pharma

Market Cap: US$31.5b

Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.

AnaptysBio

Market Cap: US$1.7b

A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.

Hisamitsu Pharmaceutical

Market Cap: US$8.2b

Manufactures and sells pharmaceuticals in Japan.

Arcus Biosciences

Market Cap: US$3.8b

A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

Corcept Therapeutics

Market Cap: US$9.1b

A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

GH Research

Market Cap: US$1.7b

Together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States.

Kodiak Sciences

Market Cap: US$2.1b

A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.

Nurix Therapeutics

Market Cap: US$2.3b

A clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.

MeiraGTx Holdings

Market Cap: US$1.1b

A clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.

UroGen Pharma

Market Cap: US$1.7b

A biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.

Capricor Therapeutics

Market Cap: US$1.8b

A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

Revolution Medicines

Market Cap: US$37.9b

A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.

Intellia Therapeutics

Market Cap: US$2.2b

Operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.

TG Therapeutics

Market Cap: US$7.6b

A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

Biogen

Market Cap: US$29.8b

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.

Alnylam Pharmaceuticals

Market Cap: US$39.1b

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

BioLife Solutions

Market Cap: US$1.3b

Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.

Dianthus Therapeutics

Market Cap: US$5.0b

A clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.

BioNTech

Market Cap: US$22.8b

Engages in the development and commercialization of immunotherapies in Germany.

Vaxcyte

Market Cap: US$7.8b

A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

Axsome Therapeutics

Market Cap: US$12.2b

A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.

Exelixis

Market Cap: US$13.4b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.